25CN-NBOH | 1391489-32-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 25CN-NBOH
• 英文别名: N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine；2-([2-(4-cyano-2,5-dimethoxyphenyl)ethylamino]methyl)phenol；Nboh-2C-CN；4-[2-[(2-hydroxyphenyl)methylamino]ethyl]-2,5-dimethoxybenzonitrile
• CAS: 1391489-32-9
• 化学式: C₁₈H₂₀N₂O₃
• 分子量: 312.368
• InChiKey: VWEDZTZAXHMZIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  74.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  8-hydroxydibenzo[b,d]furan-4-carbaldehyde 、 25CN-NBOH 在 甲醇 、 sodium tetrahydroborate 作用下， 生成
  参考文献：
  名称：

  大体积 N-二苯并呋喃基甲基取代对迷幻苯乙胺 5-HT2 受体亲和力和功效的影响

  摘要：

  在苯乙胺和色胺的胺氮原子上引入芳甲基取代基通常会导致它们对 5-HT 2血清素受体的亲和力和功能活性显着增加。为了探讨这种效应对更大的N取代基的敏感性，通过在碱性氮上添加不同的二苯并[ b , d ]呋喃甲基 (DBFM) 部分，制备了十种已充分表征的迷幻苯乙胺 2C-B 的衍生物。 DBFM 基团通过 1-、-2-或 3-位连接到氨基上，降低了对 5-HT 2A/2C受体的亲和力和激动剂活性。通过 4 位的取代通常有利于对所有三种 5-HT 2受体亚型的亲和力，其中化合物5对 5-HT 2A和 5-HT 2C受体的亲和力分别高出 10 倍和 40 倍，但选择性低于四倍三种受体亚型之间。然而，所有这些都是相对较弱的部分5-HT 2A R 激动剂，大部分在低微摩尔范围内，但在钙动员测定中确定为5-HT 2C亚型的完全或接近完全激动剂。分子对接模拟表明，二苯并呋喃部分比 5-HT 2C受体更深入地进入

  DOI：

  10.1021/acschemneuro.3c00639
• 作为产物：
  描述：

  3-(2,5-二甲氧苯基)丙酸 在 N-溴代丁二酰亚胺(NBS) 、 叠氮磷酸二苯酯 、 甲烷磺酸(2-二环己基膦基-2',4',6'-三-异丙基-1,1'-联苯基)(2'-氨基-1,1'-联苯-2-基)钯(II) 、 溶剂黄146 、 三乙胺 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 1,2-二氯乙烷 、 甲苯 、 乙腈 为溶剂， 反应 28.0h， 生成 25CN-NBOH
  参考文献：
  名称：

  [EN] PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME
  [FR] PHÉNALKYLAMINES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION

  摘要：

  本公开提供了苯基烷胺化合物及其在治疗医学疾病（如精神科疾病和障碍）中的应用。提供了制备各种苯基烷胺化合物的制药组合物和方法。

  公开号：

  WO2022192781A1

文献信息

• 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION
  申请人：Lophora ApS

  公开号：US20210137908A1

  公开（公告）日：2021-05-13

  The present invention relates to agonists of the 5-HT 2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT 2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT 2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT 2A /5-HT 2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT 2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT 2A agonist for the use in the treatment of treatment-resistant depression.

  本发明涉及5-HT2A 5-羟色胺受体的激动剂及其医疗用途。在一个方面，本发明涉及式(I)的5-HT2A激动剂。在第二个方面，本发明涉及式(II)的选择性5-HT2A激动剂。在另一个方面，本发明涉及式(III)的混合5-HT2A/5-HT2C激动剂。在另一个方面，本发明涉及用于治疗抑郁症的5-HT2A激动剂，更具体地说是用于治疗难治性抑郁症的5-HT2A激动剂。
• 5-HT2A agonists for use in treatment of depression
  申请人：Lophora ApS

  公开号：US11246860B2

  公开（公告）日：2022-02-15

  The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.

  本发明涉及 5-HT2A 血清素受体的激动剂及其医疗用途。一方面，本发明涉及式（I）的 5-HT2A 激动剂。第二方面，本发明涉及式（II）的选择性 5-HT2A 激动剂。另一方面，本发明涉及式（III）的 5-HT2A/5-HT2C 混合激动剂。再一方面，本发明涉及用于治疗抑郁障碍的5-HT2A激动剂，尤其是用于治疗耐药抑郁症的5-HT2A激动剂。
• Synthesis and Structure–Activity Relationships of <i>N</i>-Benzyl Phenethylamines as 5-HT_2A/2C Agonists
  作者：Martin Hansen、Karina Phonekeo、James S. Paine、Sebastian Leth-Petersen、Mikael Begtrup、Hans Bräuner-Osborne、Jesper L. Kristensen

  DOI：10.1021/cn400216u

  日期：2014.3.19

  N-Benzyl substitution of 5-HT2A receptor agonists of the phenethylamine structural class of psychedelics (such as 4-bromo-2,5-dimethoxyphenethylamine, often referred to as 2C-B) confer a significant increase in binding affinity as well as functional activity of the receptor. We have prepared a series of 48 compounds with structural variations in both the phenethylamine and N-benzyl part of the molecule to determine the effects on receptor binding affinity and functional activity at 5-HT2A and 5-HT2c receptors. The compounds generally had high affinity for the 5-HT2A receptor with 8b having the highest affinity at 0.29 nM but with several other compounds also exhibiting subnanomolar binding affinities. The functional activity of the compounds was distributed over a wider range with lb being the most potent at 0.074 nM. Most of the compounds exhibited low to moderate selectivity (1- to 40-fold) for the 5-HT2A receptor in the binding assays, although one compound 6b showed an impressive 100-fold selectivity for the 5-HT2A receptor. In the functional assay, selectivity was generally higher with lb being more than 400-fold selective for the 5-HT2A receptor.
• COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID
  申请人：CaaMTech, LLC

  公开号：US20190142851A1

  公开（公告）日：2019-05-16

  This disclosure pertains to new compositions and methods comprising a psilocybin derivative. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, or purified terpene.
• [EN] PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME<br/>[FR] PHÉNALKYLAMINES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：GILGAMESH PHARMACEUTICALS INC

  公开号：WO2022192781A1

  公开（公告）日：2022-09-15

  The present disclosure provides phenalkylamine compounds and their use in treating medical disorders, such as psychiatric diseases and disorders. Pharmaceutical compositions and methods of making various phenalkylamine compounds are provided.

  本公开提供了苯基烷胺化合物及其在治疗医学疾病（如精神科疾病和障碍）中的应用。提供了制备各种苯基烷胺化合物的制药组合物和方法。